Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"Adagrasib"”.
-
Targeting DNA damage repair with novel DNA-PK inhibitor, BCCA7693 to delay krasg12c inhibitor resistance: balancing cell intrinsic efficacy and immune antagonism
… MEK inhibitor trametinib and KRASG¹²C inhibitor adagrasib, at suppressing MAPK signalling and slowing tumour growth, the emergence of drug resistance demands a refined approach that targets oncogenic pathways at multiple nodes. Genomic instability is gaining recognition as a driver of resistance, …
-
The use of KRAS and CDK inhibitors in the treatment of brain metastases in pre-clinical models
… in BMs. This research explores the efficacy of adagrasib (MRTX849), a KRAS G12C inhibitor, and abemaciclib, a CDK 4/6 inhibitor, both individually and in combination against BMs originating from NSCLC cell lines harboring KRAS G12C and CDKN2A mutations. Utilizing a diverse array of methodologies …
-
Συστηματική ανασκόπηση της κλινικής ανάπτυξης των αναστολέων K-RAS G12C στο μη μικροκυτταρικό καρκίνο πνεύμονα
… με τα δύο σκευάσματα νέας γενιάς sotorasib και adagrasib. Συμπερασματικά οι μέχρι τώρα δοκιμές είναι ενθαρρυντικές, βάσει των τιμών PFS, OCD, DCR, ORR, DOR και PD που παρήχθησαν από τις κλινικές δοκιμές, και επιπλέον του δεδομένου ότι οι παρενέργειες που παρατηρήθηκαν ήταν χαμηλής κλίμακας …
-
Characterization of drug tolerant persister cells in KRAS G12C mutated lung cancer cells
… to KRAS G12C inhibitors, sotorasib and adagrasib. Drug resistance makes it harder to treat and allows for further lung cancer progression. Limited studies have provided insight on DTP cells for lung cancer with KRAS G12C mutation. In this study through public dataset single cell …
-
Mechanisms of Ras Oncogene Inhibition
… KRAS(G12C) inhibitors, sotorasib and adagrasib, revealing that adagrasib exhibits significant cross-reactivity with wildtype KRAS in vitro. Furthermore, we show that sotorasib is capable of engaging all RAS(G12C) mutants independent of isoform. Molecular dynamics simulations …
-
Therapeutic Targeting of Protocadherin 7 in Lung Adenocarcinoma
… Osimertinib, and the KRASG12C inhibitor Adagrasib. Moreover, a humanized mAb7 decreased tumor growth in an Fc-dependent manner and enhanced antibody dependent cell-mediated cytotoxicity and granzyme B production. These findings provide an important step towards the clinical development of …
-
Electronic Cigarettes Increase Blood-Brain and Blood-Tumor Barrier Drug Efflux in a Preclinical Lung Cancer Model of Brain Metastasis
… This results in reduced efficacy of adagrasib, a recently approved KRAS inhibitor that is subject to efflux at the blood-brain barrier. This work emphasizes the physiological impacts of electronic cigarettes on progression of brain metastases by reducing delivery of anti-cancer …
-
Αποτελεσματικότητα και τοξικότητα των KRAS αναστολέων στο μη-μικροκυτταρικό καρκίνο πνεύμονα (ΜΜΚΠ)
… άμεσων KRAS-G12C αναστολέων. Το Sotorasib και το Adagrasib είναι εγκεκριμένοι από τον FDA στοχευμένοι παράγοντες για προθεραπευμένους ασθενείς με KRAS-G12C μεταλλαγμένο ΜΜΚΠ. Παρά τα ενθαρρυντικά αποτελέσματα, η αποτελεσματικότητα των νέων αναστολέων είναι περιορισμένη λόγω μηχανισμών αντίστασης. …
-
Functional contribution of epithelial to mesenchymal transition program on KRASG12D targeting efficacy in pancreatic cancer
… efficacy. The emergence of KRASG12C inhibitors, Adagrasib and Sotorasib, paved the way for the development of MRTX1133, a KRASG12D inhibitor. Although MRTX1133 improved survival outcomes in pre-clinical resistance to KRASG12D inhibition develops after prolonged treatment. As such, one of the main …
-
Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
… the treatment of advanced NSCLC – Sotorasib and Adagrasib. However, reports of acquired resistance rapidly emerged. Additionally, KRasG12C mutations are rare in PDAC, with less than 5% of the reported cases showing this mutation. Therefore, despite promising candidates being reported, the …
-
Cancer drug resistance mechanisms
… 61). Existing KRAS directed agents (Sotorasib, Adagrasib) selectively target the KRAS(V12C), which account only for 1-2 percent of pancreatic cancers. Further, patients eligible for these agents develop robust resistance, limiting the long-term benefits for this treatment modality. Furthermore, …